When the U.S. Food and Drug Administration gave controversial accelerated approval to the first Alzheimer's drug in nearly 20 years, it had a surprising impact on attitudes about research into the disease. A survey by University of California, Irvine neuroscientists has found news coverage o
Researchers found and developed nanoparticles that simultaneously carry chemotherapy and a new immunotherapy. Chemotherapy is a pillar of cancer treatment, but residual cancer cells can persist and cause tumor relapse.
Cancer cells require proteins that bind copper ions in order to develop and spread throughout the human body. Recent studies on the interactions between proteins and how they bind to metals in cancer-related proteins have revealed possible new therapeutic targets.
Study revealed why metal copper are required by human cells to perform essential biological functions. The conclusion drawn from studies demonstrating higher copper levels in tumor cells and blood serum from cancer patients is that cancer cells require more copper than healthy cells.
Researchers found that how pills can help cancer and diabetic patients to manage their ailments instead of needles and injections. UCR scientists have created a chemical "tag" that can be added to these drugs, allowing them to enter blood circulation via the intestines.
Small amounts of the metal copper are required by human cells to perform essential biological functions. The conclusion drawn from studies demonstrating higher copper levels in tumor cells and blood serum from cancer patients is that cancer cells require more copper than healthy cells.
A combination of the drugs cefepime and enmetazobactam was more effective in treating both complicated urinary tract infections and acute pyelonephritis (AP), a bacterial infection causing kidney inflammation than a standard treatment combining piperacillin and tazobactam.
A combination of the drugs cefepime and enmetazobactam was more effective in treating both complicated urinary tract infections and acute pyelonephritis (AP), a bacterial infection causing kidney inflammation, than a standard treatment combining piperacillin and tazobactam.
Missouri [US], October 20 (ANI): After 14 months, there is a 70-80 per cent risk that non-small cell lung cancer, one of the two primary types of lung cancer, would become resistant to the pharmacological therapy that was initially used to treat it. There aren't many existing therapy alterna